Epigenetic Reader Domain
All Product Categories
-
Epigenetic Reader Domain Inhibitors
(341)
View all products
-
Epigenetic Reader Domain Agonists
(2)
View all products
-
Epigenetic Reader Domain Antagonists
(2)
View all products
-
Epigenetic Reader Domain Activators
(3)
View all products
-
Epigenetic Reader Domain Modulators
(2)
View all products
-
Epigenetic Reader Domain Chemicals
(2)
View all products
-
Epigenetic Reader Domain Degraders
(29)
View all products
-
Epigenetic Reader Domain Controls
(12)
View all products
-
Epigenetic Reader Domain Substrate
(1)
View all products
-
Epigenetic Reader Domain Ligands
(5)
View all products
-
Epigenetic Reader Domain Related Products (447)
Related Products (447)
-
Ziftomenib-d3
0 ImagesCat. No.: HY-132001SSynonyms: KO-539-d3Ziftomenib-d3 (KO-539-d3) is the deuterium labeled Ziftomenib (HY-132001). Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities.
-
Bromodomain inhibitor-12
0 ImagesCat. No.: HY-153668CAS No.: 2010124-06-6Bromodomain inhibitor-12 (example 303) is a bromodomain inhibitor that can be used in the research of autoimmune and inflammatory diseases.
-
UNO peptide
0 ImagesCat. No.: HY-P11462CAS No.: 2305574-44-9
-
BAY-155
0 ImagesCat. No.: HY-160018CAS No.: 2163769-52-4BAY-155 is a potent and selective menin-MLL tool inhibitor, with an IC50 of 8 nM. BAY-155 leads to a strong expression down-regulation of the MEIS1 gene and up-regulation of CD11b and MNDA genes. BAY-155 shows anti-proliferative effects in AML/ALL (acute myeloid/lymphoblastic leukemia) models.
-
VTP50469 mesylate
0 ImagesCat. No.: HY-114162BCAS No.: 2169919-27-9Synonyms: SNDX-50469 mesylateVTP50469 mesylate is a potent, and selective Menin-MLL1 inhibitor that effectively targets MLL-rearranged and NPM1c+ leukemia. VTP50469 mesylate selectively kills cell lines with MLL rearrangements and NPM1c+ mutations. VTP50469 mesylate displaces Menin from protein complexes and inhibits MLL's chromatin occupancy at specific genes, leading to significant changes in gene expression, differentiation, and apoptosis. VTP50469 demonstrates dramatic reductions in leukemia burden in patient-derived xenograft models of MLL-r acute myeloid leukemia and MLL-r acute lymphoblastic leukemia, with some mice remaining disease-free for over a year post-treatment.
-
Menin-MLL inhibitor-25
0 ImagesCat. No.: HY-157814Menin-MLL inhibitor-25 (compound A6) is a potent Menin-MLL interaction inhibitor with an IC50 value of 0.38 µM. Menin-MLL inhibitor-25 shows anti-proliferative activity. Menin-MLL inhibitor-25 induces apoptosis and cell cycle arrest at G0/G1 phase. Menin-MLL inhibitor-25 reverses the differentiation arrest.
-
Menin-MLL-IN-37
0 ImagesCat. No.: HY-181690Menin-MLL-IN-37 is an orally active Menin-MLL protein complex inhibitor with an IC50 of 820.50 nM. Menin-MLL-IN-37 disrupts the interaction between menin and MLL proteins. Menin-MLL-IN-37 induces differentiation of acute myeloid leukemia cells and selectively inhibits the proliferation of MLL-rearranged and DNMT3A/NPM1-mutant leukemia cells. Menin-MLL-IN-37 can be used for the research of acute myeloid leukemia (AML).
-
BET-IN-27
0 ImagesCat. No.: HY-168628CAS No.: 3054869-29-0BET-IN-27 (compound 6C) is an oral BET inhibitor with the IC50 values of 3.3 nM (BRD4-BD2)、3.4 nM (BRD4-BD1)、4.1 nM (BRD2-BD1)、20.4 nM (BRD3-BD1) and 42.0 nM (BRDT-BD1), respectively. BET-IN-27 shows anti-proliferative activity.
-
BiBET
0 ImagesCat. No.: HY-123626CAS No.: 2059110-46-0BiBET is a chemical probe of BET/BRD4 and is able to bind to two bromodomains simultaneously in a bivalent and cis-binding mode.
-
dBET6 (Standard)
0 ImagesCat. No.: HY-112588RCAS No.: 1950634-92-0
-
MS417 (Standard)
0 ImagesCat. No.: HY-111139RCAS No.: 916489-36-6Synonyms: GTPL7512 (Standard)MS417 (Standard) is the analytical standard of MS417 (HY-111139). This product is intended for research and analytical applications. MS417 is a selective BET-specific BRD4 inhibitor, binds to BRD4-BD1 and BRD4-BD2 with IC50s of 30, 46 nM and Kds of 36.1, 25.4 nM, respectively, with weak selectivity at CBP BRD (IC50, 32.7 μM).
-
Apabetalone (Standard)
0 ImagesCat. No.: HY-16652RCAS No.: 1044870-39-4Synonyms: RVX-208 (Standard); RVX000222 (Standard)Apabetalone (Standard) is the analytical standard of Apabetalone. This product is intended for research and analytical applications. Apabetalone (RVX-208) is an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. The IC50s are 87 μM and 0.51 μM for BD1 and BD2, respectively.
-
GSK 4027 (Standard)
0 ImagesCat. No.: HY-101027RCAS No.: 2079896-25-4GSK 4027 (Standard) is the analytical standard of GSK 4027 (HY-101027). This product is intended for research and analytical applications. GSK 4027 is a chemical probe for the PCAF/GCN5 bromodomain with an pIC50 of 7.4±0.11 for PCAF in a time-resolved fluorescence resonance energy transfer (TR-FRET) assay.
-
XD14 (Standard)
0 ImagesCat. No.: HY-110215RCAS No.: 1370888-71-3
-
BMS-986158 (Standard)
0 ImagesCat. No.: HY-101567RCAS No.: 1800340-40-2BMS-986158 (Standard) is the analytical standard of BMS-986158 (HY-101567). This product is intended for research and analytical applications. BMS-986158 is a potent BET inhibitor with IC50s of 6.6 and 5 nM in NCI-H211 small cell lung cancer (SCLC) cells and MDA-MB231 triple negative breast cancer (TNBC) cells, respectively.
-
SF2523 (Standard)
0 ImagesCat. No.: HY-101146RCAS No.: 1174428-47-7SF2523 (Standard) is the analytical standard of SF2523 (HY-101146). This product is intended for research and analytical applications. SF2523 is a highly selective and potent inhibitor of PI3K with IC50s of 34 nM, 158 nM, 9 nM, 241 nM and 280 nM for PI3Kα, PI3Kγ, DNA-PK, BRD4 and mTOR, respectively.
-
BRD7-IN-1 (Standard)
0 ImagesCat. No.: HY-111905RCAS No.: 2448414-48-8BRD7-IN-1 (Standard) is the analytical standard of BRD7-IN-1 (HY-111905). This product is intended for research and analytical applications. BRD7-IN-1, a modified derivative of BI7273 (BRD7/9 inhibitor), binds to a VHL ligand via a linker to form a PROTAC VZ185 (VZ185 against BRD7/9 with DC50s of 4.5 and 1.8 nM, respectively).
-
Ziftomenib (Standard)
0 ImagesCat. No.: HY-132001RCAS No.: 2134675-36-6Synonyms: KO-539 (Standard)Ziftomenib (Standard) is the analytical standard of Ziftomenib (HY-132001). This product is intended for research and analytical applications. Ziftomenib (KO-539) is an orally active menin-MLL interaction inhibitor with antitumor activities (WO2017161028A1, compound 151).
-
NSC 228155 (Standard)
0 ImagesCat. No.: HY-101084RCAS No.: 113104-25-9NSC 228155 (Standard) is the analytical standard of NSC 228155 (HY-101084). This product is intended for research and analytical applications. NSC 228155 is an activator of EGFR, binds to the extracellular region of EGFR and enhance tyrosine phosphorylation of EGFR. NSC 228155 is also a potent inhibitor of KIX-KID interaction, inhibits kinase-inducible domain (KID) from CREB and KID-interacting domain (KIX) from CBP, with an IC50 of 0.36 μM.
